SCHEMBL1630481

SCHEMBL1630481

N#Cc1cccc(CCNc2nc(-c3ccccc3)ccc2C(C(N)=O)c2cccnc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.41
ALDH1A1 P00352 5/20 0.41
CYP1A2 P05177 4/20 0.41
HSD17B10 Q99714 4/20 0.41
CLK4 Q9HAZ1 4/20 0.41
MAPK1 P28482 3/20 0.41
TSHR P16473 2/20 0.41
CYP2C9 P11712 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNA5 P22460 2/20 0.39
KCNH2 Q12809 2/20 0.39
GBA1 P04062 1/20 0.38
CYP2C19 P33261 4/20 0.37
ALOX15 P16050 2/20 0.37
VNN1 O95497 1/20 0.37
ATR Q13535 1/20 0.37
SCN9A Q15858 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631443 0.89 NPC1 (0.45) ALDH1A1MEN1KMT2AGBA1NPC1
SCHEMBL1631415 0.88 GBA1 (0.45) ALDH1A1MEN1KMT2AGBA1NPC1
SCHEMBL1631787 0.88 GBA1 (0.51) ALDH1A1MEN1KMT2AKCNA5GBA1
SCHEMBL1630102 0.88 CSNK2A2 (0.44) ALDH1A1MEN1KMT2AKCNA5GBA1
SCHEMBL1632043 0.88 ALDH1A1 (0.40) CYP3A4ALDH1A1CYP1A2HSD17B10MAPK1
SCHEMBL1632258 0.87 ADORA2A (0.43) CYP3A4ALDH1A1CYP1A2HSD17B10CLK4
SCHEMBL1632284 0.85 CSNK2A2 (0.46) CYP3A4CYP1A2CLK4MAPK1TSHR
SCHEMBL4120643 0.85 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2AKCNA5
SCHEMBL1630349 0.85 KDM4E (0.41) ALDH1A1HSD17B10MAPK1MEN1USP2
SCHEMBL1629879 0.84 GBA1 (0.39) ALDH1A1GBA1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 CYP3A4 2030/4885ALDH1A1 1756/4885CYP1A2 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.